Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2020-03-20 Regulatory Filings
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma regains worldwide rights to Amylin analog program from Boehringer Ingelheim
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a change in a licensing agreement (regaining rights to a drug program). It does not fit into specific categories like financial reports, board changes, or dividend notices. As it is a general corporate announcement regarding business operations and partnerships, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback.
2020-03-20 English
M&A Activity 2020
M&A Activity Classification · 99% confidence The document is a 'Company announcement – No. 07 / 2020' from Zealand Pharma detailing the regaining of worldwide rights to an Amylin analog program from Boehringer Ingelheim. This is a specific corporate action announcement, not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a standard earnings release (ER). It announces a change in licensing/collaboration status, which is a significant business development. While it could potentially fall under RNS (Regulatory Filings), the content is highly specific to business operations and strategic partnerships. Given the options, it most closely resembles a general corporate update or announcement that doesn't fit the other specific categories like M&A (TAR) or Capital Change (CAP). However, since it is a formal announcement of a significant business event (reacquiring rights), and it is not explicitly a management change (MANG), financing (CAP), or legal matter (LTR), it fits best as a general Regulatory Filing (RNS) or potentially a miscellaneous corporate announcement. Since it is a formal press release announcing a business event, RNS is the most appropriate fallback for specific corporate news not covered elsewhere. The document length is short (4039 chars) and it includes an 'Attachment' link, suggesting it might be an announcement *of* a filing or report, but the core content is the announcement itself. I will classify it as RNS as it is a general regulatory/corporate announcement.
2020-03-20 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It explicitly lists the name of the executive (Adam Steensberg), his position, the nature of the transaction (sale of shares), the price, volume, and the date of the transaction. This is a classic insider trading disclosure, which corresponds to the 'Director's Dealing' category.
2020-03-20 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies a specific executive (Adam Steensberg), his position, the issuer (Zealand Pharma A/S), and details of a transaction involving financial instruments (warrants/shares). This matches the definition for 'Director's Dealing' (DIRS).
2020-03-20 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is titled 'Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons'. This is a standard regulatory disclosure for insider trading or director dealings. While the document mentions 'Please see the attached files', the core content is the notification of director/managerial dealings, which falls under the 'Director's Dealing' category.
2020-03-20 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is an official announcement regarding transactions in company shares by persons discharging managerial responsibilities (PDMRs). This is a classic 'Director's Dealing' notification, which is required under market abuse regulations. Although the document mentions 'attached files', the text itself is the primary notification of these insider transactions, fitting the definition of DIRS.
2020-03-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.